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Huntington’s disease (HD) is a progressive neurodegenerative disorder caused by a CAG-
polyglutamine repeat expansion in the huntingtin (htt) gene. We found that peroxisome 
proliferator-activated receptor delta (PPARδ) interacts with htt and that mutant htt represses 
PPARδ-mediated transactivation. Increased PPARδ transactivation ameliorated mitochondrial 
dysfunction and improved cell survival of HD neurons. Expression of dominant-negative PPARδ 
in CNS was sufficient to induce motor dysfunction, neurodegeneration, mitochondrial 
abnormalities, and transcriptional alterations that recapitulated HD-like phenotypes. Expression of 
dominant-negative PPARδ specifically in the striatum of medium spiny neurons in mice yielded 
HD-like motor phenotypes, accompanied by striatal neuron loss. In mouse models of HD, 
pharmacologic activation of PPAR δ, using the agonist KD3010, improved motor function, 
reduced neurodegeneration, and increased survival. PPAR δ activation also reduced htt-induced 
neurotoxicity in vitro and in medium spiny-like neurons generated from human HD stem cells, 
indicating that PPAR δ activation may be beneficial in individuals with HD and related disorders.
The PPARs are ligand-activated transcription factors that belong to the nuclear hormone 
receptor superfamily. The three subtypes, termed PPARα, - δ, and -γ, serve as lipid sensors 
in response to increased energy requirements
1
. PPARs are activated by lipids and fatty acid 
derivatives, and perform essential functions in lipid homeostasis, glucose metabolism, 
energy production, and cellular differentiation.
The least-studied member of the PPAR nuclear receptor family is PPAR δ, which shows a 
fairly ubiquitous expression pattern, but is highly abundant in skeletal muscle and brain
2,3. 
The function of PPAR δ has been studied in skeletal muscle, where PPAR δ regulates 
skeletal muscle energy metabolism and mitochondrial biogenesis
4,5. Indeed, PPAR δ 
promotes mitochondrial biogenesis and regulates fiber type switching in muscle
6,7. PPAR δ 
is at least two-fold more highly expressed in brain than in muscle
8
, making it the most 
abundant PPAR subtype in the CNS, but its functional relevance there remains unknown.
HD is a progressive autosomal dominant neurodegenerative disorder in which patients 
develop motor and cognitive impairment
9
. Although the mutant htt protein is widely 
expressed, neurodegeneration and atrophy occur principally in medium-sized spiny neurons 
(MSNs) of the striatum and cerebral cortex pyramidal neurons that project to the striatum
10
. 
In 1993, a CAG trinucleotide repeat expansion mutation in the coding region of the htt gene 
was identified as the cause of HD
11
. Htt glutamine tracts that exceed a certain length 
threshold (approximately 37 repeats in HD) adopt a pathogenic conformation, yielding 
conformers that are resistant to the normal processes of protein turnover, resulting in the 
accumulation of pathogenic mutant htt, cellular toxicity, and neurodegeneration
12
.
Neurons in the brain have high energy demands and require mitochondrial production of 
ATP. Chronic administration of a mitochondrial toxin, 3-nitropropionic acid, results in 
selective loss of MSNs in the striatum
13
. This finding has been corroborated in HD cell 
culture models, mice, and samples from HD individuals (reviewed in 
14
), and suggested that 
mitochondrial dysfunction may underlie HD pathogenesis and account for the cell-type 
specificity. At the same time, the necessity of htt nuclear localization for HD disease 
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pathogenesis highlighted nuclear pathology as a likely early step in the neurotoxicity 
cascade
15
. N-terminal fragments of mutant htt protein interfere with gene transcription in the 
early stages of the HD disease process (reviewed in 
16
). We, and others linked the 
mitochondrial dysfunction and metabolic defects in HD to transcriptional dysregulation of 
peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α), a co-
activator that controls a network of transcriptional programs that culminate in mitochondrial 
biogenesis and enhanced energy production
17–19. The importance of PGC-1α for HD 
pathogenesis is underscored by the observation that PGC-1α over-expression in HD mice is 




When an unbiased screen for htt-interacting proteins yielded PPARs as candidate interactors, 
we evaluated the different PPARs, and documented an interaction between PPARδ and htt. 
We investigated the role of PPARδ repression in HD, and determined that transcriptional 
dysregulation of PPARδ underlies HD mitochondrial dysfunction and neurodegeneration. By 
directing expression of dominant-negative PPARδ to the CNS or specifically to MSNs in 
striatum, we demonstrated that expression of dominant-negative PPARδ is sufficient to 
produce motor phenotypes, neurodegeneration, mitochondrial defects, and transcriptional 
abnormalities that parallel disease phenotypes in HD. In light of these results, we evaluated 
the PPARδ agonist KD3010 as a therapy for HD, and found that KD3010 could ameliorate 
HD phenotypes in transgenic mice and in striatal medium spiny-like neurons derived from 
induced pluripotent stem cells from HD individuals. Our findings offer novel insights into 
the pathogenesis of HD, provide evidence for an unexpectedly crucial role for PPARδ in 
maintaining neural health, and highlight a promising therapeutic strategy for HD and related 
neurodegenerative disorders.
Results
Huntingtin and PPARδ physically interact
To identify transcription factors that interact with htt, we transfected HEK293 cells with 
GFP-tagged N-terminal htt protein, immunoprecipitated GFP-htt-25Q, and applied the 
htt-25Q immunoprecipitated material to a transcription factor binding site array. This 
unbiased screen yielded PPAR response element (PPRE) binding proteins as candidate 
interacting proteins (Supplementary Fig. 1a), and led us to examine whether htt interacts 
with one of the PPARs. To test this hypothesis, we performed transient transfections of 
HEK293 cells with GFP-htt-25Q, GFP-htt-104Q, or empty GFP vector, and with Flag-
tagged PPARα, PPARδ, or PPARγ. After GFP immunoprecipitation, we immunoblotted with 
anti-Flag antibody and detected PPARδ in htt-25Q and htt-104Q immunoprecipitates, but 
found no evidence for an interaction between htt and PPARα, or htt and PPARγ (Fig. 1a). 
Quantification of PPARδ band intensity upon htt immunoprecipitation indicated that the 
polyQ tract expansion promotes greater interaction between PPARδ and htt (Supplementary 
Fig. 1b). PPARδ is the most abundantly expressed PPAR subtype in the CNS
8
; however, its 
functional relevance in CNS is ill-defined. To determine if endogenous PPARδ and htt 
interact, we performed co-immunoprecipitations in ST-Hdh striatal-like cells. After 
immunoprecipitation of htt with an antibody directed against its C-terminus (Supplementary 
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Fig. 1c) and immunoblotting with a PPARδ-specific antibody, we found that PPARδ interacts 
with full-length htt in Q7/Q7, Q7/Q111, and Q111/Q111 ST-Hdh cells (Fig. 1b). To establish 
if this interaction occurs in the CNS under physiological conditions, we performed co-
immunoprecipitation on protein lysates isolated from the cortex of BAC-HD97 mice
21
. 
When we immunoprecipitated htt and immunoblotted with a PPARδ-specific antibody, we 
detected PPARδ protein in BAC-HD and non-transgenic mice (Fig. 1c). We then 
immunoprecipitated PPARδ and upon immunoblotting with a htt-specific antibody, we 
observed both polyQ-htt and endogenous htt protein in PPARδ immunoprecipitates from 
BAC-HD cortex, and detected endogenous htt in PPARδ immunoprecipitates from non-
transgenic cortex (Fig. 1d). Finally, to determine the nature of the interaction, we performed 
in vitro transcription and translation of PPARδ and GFP-htt-Q25 (aa 1-171), and then did a 
pull-down with a GFP or IgG-specific antibody. Immunoblotting of the pull-down material 
yielded PPARδ protein for the GFP immunoprecipitation, but not for the IgG 
immunoprecipitation (Fig. 1e). These findings indicate that PPARδ and htt physically 
interact in the CNS.
Altered PPARδ transactivation contributes to HD mitochondrial dysfunction and 
neurotoxicity
We evaluated the effect of polyQ-htt on PPARδ transactivation by co-transfecting N-
terminal truncated htt (exon 1+2) and a 3x-PPAR response element (3x-PPRE) luciferase 
reporter into HEK293 cells, and noted polyQ length-dependent inhibition of PPARδ 
transactivation upon treatment with the PPARδ selective agonist GW501516 (Supplementary 
Fig. 2a). We then measured PPARδ transactivation in ST-Hdh striatal-like cells, and found 
that PPARδ transactivation was significantly repressed in a polyQ length-dependent fashion, 
but could be partially rescued by either PPARδ or PGC-1α, and fully rescued with PPARδ 
and PGC-1α together (Supplementary Fig. 2b). To examine the role of PPARδ transcription 
repression in HD neurons, we repeated the transactivation assays in primary cortical neurons 
from BAC-HD mice, and observed significantly impaired PPARδ transactivation at baseline, 
upon co-transfection with PPARδ or PGC-1α, and in response to co-transfection of PPARδ 
and PGC-1α together (Fig. 2a). When we measured mitochondrial membrane potential, we 
noted significantly reduced mitochondrial membrane potential in BAC-HD neurons (Fig. 
2b). Importantly, over-expression of PPARδ, via infection with PPARδ lentivirus, or 
treatment with GW501516 rescued mitochondrial membrane polarization alterations in 
BAC-HD neurons, with combined PPARδ over-expression and GW501516 treatment 
resulting in the most robust effect (Fig. 2b). Caspase-3 activation was elevated and MAP2 
immunoreactivity reduced in BAC-HD neurons, as compared to non-transgenic primary 
cortical neurons, indicating that HD neurons are more susceptible to cell death (Fig. 2c). We 
noted increased MAP2 staining and reduced caspase-3 activation in BAC-HD neurons 
transduced with PPARδ lentivirus in the presence of GW501516 (Fig. 2c). Increased PPARδ 
expression, GW501516 treatment, or PPARδ in combination with GW501516 could rescue 
cell death in BAC-HD neurons (Fig. 2d). Analysis of MAP2 immunoreactivity in BAC-HD 
neurons independently corroborated these results (Supplementary Fig. 2c).
We have previously shown that altered transcriptional activity of PGC-1α contributes to HD 
pathogenesis, with significant reductions in PGC-1α targets in HD mice and human 
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. Although the expression of PGC-1α is reduced in HD, the magnitude of the 
decreases cannot fully account for the transcriptional alterations documented in HD, 
indicating that a PGC-1α-dependent transcription factor could be responsible for the 
transcriptional dysregulation. As PPARδ and htt physically interact in the CNS, and specific 
PPARδ target genes exhibit reduced expression in BAC-HD striatum, we postulated that 
impaired PPARδ function accounts for altered PGC-1α transcriptional activity in HD. Gene 
set analysis of striatal Affymetrix U133A/B microarray expression data from human HD 
individuals revealed significant alterations in 12 of 16 principal PPARδ target genes (P < 
10−4, χ2) (Supplementary Fig. 3a), consistent with this hypothesis.
Physical interaction of polyQ-htt with PPARδ promotes HD neurotoxicity
To determine the physiological relevance of the PPARδ – htt interaction, we examined 
striatal sections from HD N171-82Q transgenic mice, and observed co-localization of 
polyQ-htt protein with PPARδ (Supplementary Fig. 3b). To test whether disruption of this 
interaction would prevent polyQ-htt neurotoxicity, we created PPARδ expression constructs 
with deletions of different PPARδ domains (Supplementary Fig. 4a). HEK293 cell co-
transfections with GFP-tagged htt expression constructs and PPARδ domain deletion 
constructs, followed by co-immunoprecipitation, enabled mapping of the htt interaction site 
to the D domain (hinge region) of PPARδ (Supplementary Fig. 4b). To determine if physical 
interaction between polyQ-htt and PPARδ is necessary for neurotoxicity, we co-expressed 
different PPARδ deletion mutants in combination with full-length PPARδ in ST-Hdh Q111/
Q111 striatal-like cells. Although co-expression of PPARδ lacking either the A – C domain 
or the E – F domain prevented polyQ-htt transcriptional repression, mitochondrial 
membrane depolarization, and cell death, co-expression of PPARδ lacking the D – F domain 
did not rescue any of these neurotoxicity phenotypes (Supplementary Fig. 5). These findings 
indicate that competition for mutant htt interaction with PPARδ deletion constructs 
specifically retaining the D domain is sufficient to blunt polyQ-htt neurotoxicity, 
underscoring the importance of the interaction for HD pathology.
Previous studies have implicated PPARγ transcriptional alterations in HD pathogenesis
22–24. 
To examine the potential contribution of PPARα or PPARγ dysfunction to polyQ-htt 
neurotoxicity, we surveyed PPAR expression in CNS. Immunohistochemistry analysis of 
sections from the cortex of control mice revealed prominent neuronal expression of PPARδ, 
modest neuronal expression of PPARα, and barely detectable neuronal expression of PPARγ 
(Fig. 2e). In the cortex, striatum, and cerebellum of BAC-HD mice and non-transgenic 
littermates, prominent neuronal expression of PPARδ was observed, with limited expression 
of PPARα and PPARγ (Supplementary Fig. 6). These findings were corroborated upon 
immunoblotting of cortical lysates, cortical neurons, cerebellar lysates, and cerebellar 
granule neurons from BAC-HD and non-transgenic mice (Supplementary Fig. 7a–d). To 
directly determine the contribution of the different PPARs to polyQ-htt neurotoxicity, we 
cultured primary cortical neurons from BAC-HD mice and monitored cell death upon knock-
down or agonist activation of each PPAR. Cell death was increased in BAC-HD neurons in 
which PPARδ was silenced by shRNA, while knock-down of PPARα or PPARγ did not 
affect cell death (Fig. 2f). Similarly, treatment with a PPARδ agonist reduced cell death in 
comparison to PPARα or PPARγ agonist-treated BAC-HD neurons (Fig. 2f).
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To evaluate the contribution of PPARδ transcriptional alterations to HD pathogenesis in vivo, 
we measured the expression of 11 PPARδ target genes in the striatum of BAC-HD transgenic 
mice, and noted reductions for all tested PPARδ target genes in BAC-HD striatum 
(Supplementary Fig. 7e). RT-PCR analysis confirmed significant reductions in the 
expression levels of PPARδ targets in ST-Hdh Q111/Q111 striatal-like cells in comparison to 
Q7/Q7 cells (Fig. 3a). We then performed chromatin immunoprecipitation and found that 
PPARδ occupancy is reduced at the promoters of its target genes in Q111/Q111 striatal-like 
cells (Fig. 3a), suggesting that PPARδ binding to target promoters is prevented upon 
interacting with polyQ-htt.
Dominant-negative PPARδ expression in the CNS induces motor abnormalities, 
mitochondrial defects, and neurodegeneration
To determine if impaired PPARδ transactivation function is sufficient to elicit 
neurodegeneration in vivo, we derived a conditional transgenic PPARδ expression construct 
containing a single amino acid mutation, substituting proline for glutamate at residue 411 
(Supplementary Fig. 8a). The E411P mutation inhibits PPARδ transactivation in a dominant-
negative fashion
25,26. After generating CAGGS-floxed STOP-PPARδ-E411P transgenic 
mice, we evaluated these mice for signs of systemic or neurological phenotypes, and did not 
detect any evidence of abnormality. We then crossed these mice with CMV-Cre driver mice 
to permit widespread expression of PPARδ-E411P, and akin to PPARδ knock-out mice
27
, we 
found that ubiquitous expression of PPARδ-E411P protein causes prenatal lethality. We next 
crossed the CAGGS-floxed STOP-PPARδ-E411P mice with Nestin-Cre mice to obtain 
bigenic Nestin-Cre;PPARδ-E411P mice, as the Nestin-Cre driver promotes expression of 
Cre recombinase throughout the neural lineage
28
. PPARδ-E411P protein was expressed at 
1.5 to 2x endogenous PPARδ protein. Characterization of Nestin-Cre;PPARδ-E411P mice, in 
comparison to singly transgenic Nestin-Cre and CAGGS-floxed STOP-PPARδ-E411P mice, 
indicated that Nestin-Cre;PPARδ-E411P bigenic mice appear smaller by 4 – 6 months of 
age, such that by 8 months of age, they weigh less than littermate controls (Fig. 3b). 
Phenotype evaluation, using a neurological examination screening tool
29
, revealed that 
Nestin-Cre;PPARδ-E411P mice suffer prominent motor abnormalities by 8 months of age 
(Fig. 3c–e). Testing of Nestin-Cre;PPARδ-E411P mice on an accelerating rotarod confirmed 
motor impairment (Fig. 3f), while stride length analysis and grip strength testing provided 
further evidence for motor abnormalities (Fig. 3g). We also evaluated learning and memory 
in Nestin-Cre;PPARδ-E411P mice, and documented reduced novel object recognition and 
reduced novel environment exploration (Supplementary Fig. 8b–d).
Ultrastructural analysis of Nestin-Cre;PPARδ-E411P mice revealed that mitochondria in the 
striatum appear smaller in size (Fig. 3h), in agreement with previous studies of HD
30,31, as 
mitochondrial area and perimeter in the cortex and striatum was reduced (Fig. 3i). To 
evaluate metabolic function, we measured mitochondrial complex activities. Although 
mitochondrial complex I and II activities in Nestin-Cre;PPARδ-E411P and control mice 
were similar, mitochondrial complex IV and V activities were reduced in the striatum of 
Nestin-Cre;PPARδ-E411P mice (Supplementary Fig. 9a–d), and the overall ATP 
concentration was reduced in the striatum and cortex (Fig. 3j). Quantitative PCR analysis of 
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mitochondrial and nuclear genomic DNA content corroborated abnormalities in 
mitochondrial bioenergetics in Nestin-Cre;PPARδ-E411P mice (Supplementary Fig. 9e).
Brain size in adult Nestin-Cre;PPARδ-E411P mice was markedly reduced in comparison to 
littermate controls (Fig. 4a). Comparable reductions in the volume of the cortex and the 
basal ganglia were noted in Nestin-Cre;PPARδ-E411P mice (Fig. 4b,c). NeuN staining of 
Nestin-Cre;PPARδ-E411P brain sections revealed reduced neuron numbers (Fig. 4d). This 
was paralleled by a reduction in tyrosine hydroxylase (TH)-positive neurons in substantia 
nigra (Fig. 4e), decreased MAP2 immunostaining in the cortex and hippocampus (Fig. 4f), 
and reactive gliosis, as assessed by GFAP immunostaining, in the brains of Nestin-
Cre;PPARδ-E411P mice (Fig. 4g). Hence, mice expressing a dominant-negative version of 
PPARδ in the CNS develop striking neurological abnormalities in the context of profound 
neurodegeneration.
Dominant-negative PPARδ expression in striatum induces Huntington’s disease-like 
neuronal and molecular pathology
To assess the impact of PPARδ transcription interference in just the striatum, we obtained 
the Rgs9-Cre line, which restricts expression of Cre recombinase to striatal MSNs
32
, to 
derive bigenic Rgs9-Cre;PPARδ-E411P mice. Although Rgs9-Cre;PPARδ-E411P mice are 
of similar size and weight as gender-matched littermate controls, Rgs9-Cre;PPARδ-E411P 
mice develop motor abnormalities, as assessed by composite neurological examination
29
, 
rotarod analysis, and grip strength testing (Fig. 5a–e). Neuropathology examination of Rgs9-
Cre;PPARδ-E411P mice revealed evidence for decreased striatal neuron number (Fig. 5f,g), 
due to a reduction in parvalbumin immunoreactive neurons, as acetylcholinesterase-positive 
neurons were spared (Supplementary Fig. 10). This pattern is consistent with striatal neuron 
loss observed in HD patients
33,34. As CAGGS-floxed STOP-PPARδ-E411P transgenic 
crosses with the Nestin-Cre and Rgs9-Cre driver lines yielded distinct patterns of 
neurodegeneration that reflect Cre recombinase expression, observed phenotypes cannot be 
attributed to insertional mutagenesis.
Another defining feature of HD pathogenesis is transcriptional abnormalities
16
. Using RNA-
Seq analysis to assess the striatal transcriptomes of Nestin-Cre;PPARδ-E411P mice, we 
found that 583 genes in Nestin-Cre;PPARδ-E411P striatum were altered in their expression 
in comparison to littermate controls. We performed Gene Ontology analysis on this 583-
gene set, identified altered Biofunction pathways, and represented these Biofunction 
pathways in proportion to the percentage of total altered genes for each significantly 
perturbed pathway (Fig. 5h). To determine if the transcriptome changes found in the striatum 
of Nestin-Cre;PPARδ-E411P mice overlap with changes observed in HD brains, we 
performed Gene Ontology analysis on genes altered in their expression in the caudate of 
individuals with HD
35
, and represented the detected Biofunctions pathways in proportion to 
the percentage of total altered genes for each pathway (Fig. 5h). Ordering of altered 
Biofunctions pathways, for the human HD caudate transcriptome and Nestin-Cre;PPARδ-
E411P striatum transcriptome (Supplementary Table 1), revealed nearly identical 
Biofunctions pathway rankings (P < 10−11). To validate gene expression alterations 
identified by RNA-Seq analysis, we performed qRT-PCR analysis on striatal RNAs from 
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Nestin-Cre;PPARδ-E411P mice for 11 genes, and documented altered expression for 10 of 
the 11 tested genes, all in the predicted direction (Supplementary Fig. 11a). Finally, to assess 
the specificity of polyQ-htt repression of PPARδ, we performed 3x-PPRE reporter assays in 
HEK293 cells transfected with ataxin-7-10Q or ataxin-7-92Q, and found that polyQ-ataxin-7 
did not repress PPARδ transactivation (Supplementary Fig. 11b).
The PPARδ agonist KD3010 rescues neurological phenotypes and neurodegeneration




phenyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid tosylate), is a highly selective and 
potent PPARδ agonist
37
. KD3010 in the low nanomolar range rescued PPARδ transcriptional 
repression and mitochondrial dysfunction in BAC-HD neurons, and could prevent cell death 
in primary cortical neurons transfected with a 586 amino acid N-terminal htt fragment 
containing 82 glutamines (Supplementary Fig. 12a–c). Intraperitoneal (i.p.) injection of 15 
mg/kg of KD3010 into C57BL/6J mice resulted in ~10% brain/plasma ratios at 2 – 24 h 
post-injection (Supplementary Table 2). To test if KD3010 could promote PPARδ 
transactivation in brains of living mice, we injected 50 mg/kg /day of KD3010 and found 
that this treatment induced the expression of PPARδ target genes (Supplementary Fig. 12d). 
KD3010 did not cause weight loss or visible side effects, nor did we find any evidence of 
organ toxicity. Hence, KD3010 at 50 mg/kg /day is tolerated in mice and can promote 
PPARδ transactivation function in the mammalian CNS.
The HD N171-82Q mouse model recapitulates HD-like motor phenotypes and 
neurodegeneration within a time frame of 5 – 6 months
38
. Beginning at 6 weeks of age, HD 
mice were injected with either 50 mg/kg /day of KD3010 or vehicle, 5 times per week. 
Importantly, we adhered to recommended preclinical trial guidelines, intended to avoid 
spurious results
39,40. We tracked the progression of disease phenotypes in vehicle-treated 
and agonist-treated HD mice by performing composite neurological examination
29
, rotarod 
analysis, and grip strength testing at 4 week intervals. KD3010 treatment attenuated 
neurological dysfunction and improved motor function in HD mice, as compared to vehicle-
treated controls (Fig. 6a–b, Supplementary Fig. 12e–g). Striatal choline acetyltransferase 
(ChAT) levels, a measure of striatal interneuron dysfunction in HD
33
, were increased, 
aggregated htt protein was reduced, and striatal volume was maintained in KD3010-treated 
HD mice (Fig. 6c, Supplementary Fig. 13). In addition to rescuing neurological phenotypes 
and neurodegeneration, KD3010 yielded a 16% extension in mean lifespan in HD mice (Fig. 
6d). Finally, we differentiated human HD induced pluripotent stem cells into striatal medium 
spiny-like neurons, and treated these human HD medium spiny-like neurons with KD3010. 
While the inactive enantiomer of KD3010 did not offer any protection from cell death, 
KD3010 rescued cell death in neurons derived from HD individuals (Fig. 6e).
Discussion
Here we document PPARδ transcription interference as a cause of the bioenergetics defects 
and mitochondrial abnormalities in HD. In addition to demonstrating that htt represses 
PPARδ transactivation in an interaction-dependent fashion to yield mitochondrial defects 
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and neurotoxicity in a variety of model systems, we generated transgenic mice expressing 
dominant-negative PPARδ to recapitulate HD-like behavioral, metabolic, and transcriptional 
phenotypes. As interfering with PPARδ function in mice can phenocopy HD, our findings 
implicate PPARδ dysregulation as a key node in the HD pathogenic cascade.
Of the three PPARs, the least-studied member of this family is PPARδ. We found that 
treatment with a PPARδ-selective agonist evoked a robust response in transactivation assays, 
and demonstrated that PPARδ could elicit neuroprotection in HD primary neurons. To clarify 
the role of PPARδ vis-à-vis PPARα and PPARγ, we modulated each PPAR individually by 
shRNA knock-down or agonist treatment, and found that only PPARδ modulation yielded 
highly significant effects on HD neurotoxicity. We documented that PPARδ is much more 
highly expressed than PPARα or PPARγ in neurons of the cortex and striatum, in agreement 
with previous work
41
. While studies have shown that PPARγ agonist treatment can 
ameliorate disease phenotypes in HD
22,42,43, the beneficial effects of PPARγ agonist therapy 
likely stem from improved function in peripheral tissues, in hypothalamic neurons, and in 
non-neural CNS cells
41
. As our studies suggested an important role for PPARδ in neural 
function, we generated lines of conditional transgenic PPARδ mice, and directed expression 
of dominant-negative PPARδ to neurons throughout the CNS or just to striatal MSNs. These 
experiments revealed that PPARδ is necessary for normal neural function, as profound 
neurological and neurodegenerative phenotypes emerged in mice expressing dominant-
negative PPARδ in neural lineages. Our findings thus identify neurons as a cell type where 
PPARδ is essential for homeostasis.
If impaired PPARδ function is contributing to HD pathogenesis, we theorized that an 
attractive treatment option would be to agonize PPARδ. Of various possible PPARδ agonists, 
we opted for KD3010, as this PPARδ agonist is potent and specific, crosses the blood-brain 
barrier, and was approved for use in humans in a Phase 1b metabolic disease safety trial, 
where no incidences of side effects were reported. We performed a preclinical trial of 
KD3010 in HD N171-82Q transgenic mice, and observed compelling evidence for 
therapeutic efficacy. To further evaluate KD3010 as a treatment for HD, we tested KD3010 
in human HD striatal medium spiny-like neurons derived from induced pluripotent stem 
cells, and documented robust neuroprotection in the nanomolar range. Our findings strongly 
suggest that repurposing PPARδ agonists capable of crossing the blood brain barrier is a 
viable treatment strategy for HD, and indicate that KD3010 should be pursued as a lead. As 
mitochondrial dysfunction and transcription interference with PGC-1α, the co-activator for 
PPARδ are recognized features of Parkinson’s disease (PD) pathogenesis
44,45, and we 
observed marked loss of TH+ neurons in the substantia nigra of dominant-negative PPARδ 
conditional transgenic mice, PPARδ agonist therapy should also be considered as a treatment 
for PD.
Another facet of PPARδ biology with relevance to therapy development for 
neurodegenerative disease is that PPARδ forms a heterodimer with RXR, and RXR agonists 
are capable of promoting PPARδ transactivation
46
. Bexarotene is a synthetic drug, approved 
for use in humans, which is structurally similar to retinoic acid compounds that are known 
endogenous RXR ligands. One provocative study reported that administration of bexarotene 
to Alzheimer’s disease (AD) mice yielded dramatic improvements in cognitive, social, and 
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olfactory deficits, accompanied by improved neural circuit function and enhanced clearance 
of soluble Aβ oligomers
47
. As PPARδ is highly expressed in neurons of the CNS
8
, and 
bexarotene would potently activate PPARδ, our results indicate that enhanced PPARδ 
activation could be contributing to bexarotene neuroprotection in AD
47,48.
As the PPARδ – PGC-1α pathway promotes the expression of genes that drive high-level 
energy production and insure protein and organelle quality control, the neuroprotective 
effects of agonizing this pathway likely stem from boosting neuronal bioenergetics and 
proteostasis. HD, PD, and AD are all late-onset disorders, implying that a decline in the 
function of crucial homeostatic pathways with age is a central factor in the development of 
clinical disease. In HD, this view is all the more relevant, as affected patients express the 
mutant disease protein from the time of conception, yet can go more than five or even six 
decades without obvious symptoms. It seems reasonable to propose that activation of 
pathways promoting energy production (which is always under high demand in neurons and 
CNS cells) and supporting protein – organelle quality control (which constitutes a major 
challenge for neurons and other CNS cell types) might stave off cellular decompensation in 
the face of proteotoxic stress during this long prodromal phase. Thus, therapies directed at 




RNA samples were isolated using Trizol (Life Technologies). Genomic DNA was removed 
using RNAse free DNAse (Ambion). mRNA quantification was performed using the 7500 
Real Time PCR System (ABI) with ABI Assays-on-Demand primers and TaqMan® based 
probes. ABI TaqMan primer and probe set designations are available upon request. 18S 
RNA was used as internal control. Relative expression levels were calculated via the ΔΔCt 
method.
Cell culture and primary neuron studies
ST-Hdh cells were cultured as previously described
20
. Primary cortical neurons were 
prepared as previously described
50
. HEK293T cells were cultured as previously 
described
19,20. HEK293T cells tested negative for mycoplasma contamination, and were 
used for the purposes of preliminary testing prior to confirmation of results in multiple more 
physiologically relevant model systems, due to their robust protein expression levels of 
transfected proteins. Co-transfection with the indicated constructs (previously described
19
) 
was done with Lipofectamine 2000, as per manufacturer’s protocol (Invitrogen). Addgene 
provided constructs for PPARα (22751) and PPARγ (8895). PPARδ-Flag (Origene, 
MR207001) truncation constructs [ΔA–C (Δ1-141), ΔA–D (Δ1-214), ΔD–F (Δ143-440), and 
ΔE–F (Δ215-440)] were made by standard techniques and verified by sequencing. Lentiviral 
transduction was used to induce gene expression or knockdown in primary neurons, with 
infection achieved by adding 1 x 107 titer units of lentivirus to the culture media. For co-
transfection assays, cells were drug-treated 24 h after reporter transfection, harvested 24 h 
later, and subjected to analysis using the Dual-Luciferase® Reporter Assay system 
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(Promega). Mitochondrial membrane potential in primary cortical neurons was measured via 
live cell loading with a potential-sensitive dye, JC-1, using the Tecan M200Pro Reader. 
Analysis of cell death with immunofluorescence to activated caspase-3 and evaluation of 
MAP2 immunoreactivity to gauge neuron health was performed as described
51
. In all 
experiments, the investigator was blinded to culture conditions and cell treatments. 
Compound concentrations: fenofibrate (Sigma, 100 nM), GW501516 (Santa Cruz, 100 nM), 
pioglitazone (Sigma, 20 nM), and H2O2 (Sigma, 25 μM).
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed as previously described
20
. Briefly, St-Hdh cells were cross-
linked with 1.0% formaldehyde. After sonication, lysates were incubated with PPARδ 
antibody (sc-7197, Santa Cruz Biotechnology, 1:100) or control rabbit IgG (Santa Crux 
Biotechnology, 1:100). Quantitative PCR analysis was performed with the SYBR-Green 
PCR master mix (ABI) on a 7500 Real Time PCR System (ABI).
Mouse studies
All animal experimentation adhered to NIH guidelines and was approved by and performed 
in accordance with the University of Washington Institutional Animal Care and Use 
Committee and the UCSD Institutional Animal Care and Use Committee. The pCAGGS-
loxP-STOP-loxP murine wild-type PPARδ transgenic construct
52
 was altered with the 
E411P mutation
25
, and then prepared for pronuclear injection. Resulting transgenic mice 
were crossed with Cre hemizygous mice to derive floxed-STOP PPARδ E411P – Cre driver 
bigenic mice. All HD transgenic, PPARδ transgenic, and Cre driver lines were backcrossed 
onto the C57BL/6J strain background for >9 generations, before genetic crosses were 
performed for purposes of experimentation. Blinded observers visually inspected mice for 
obvious neurological signs and examined mice with a composite neurological evaluation 
tool [Ledge test, clasping, kyphosis, and gait were scored on a scale of 0 (normal) to 3 
(severely impaired)], as described previously
53
. Blinded investigators examined motor 
phenotypes, by performing rotarod testing, as well as grip strength and stride length 
analysis, as previously described
20
. Cohort sizes were designated based upon power analysis 
for threshold effects of at least 25% difference. Novel object recognition and Y maze spatial 
memory testing were performed by blinded investigators as previously described
54
.
For neuropathology experiments, brains were harvested as described
20
. Histopathology, 
volume measurements, and stereology analysis were performed, as previously described
20
. 
For PPAR expression analysis, brain sections were incubated with: NeuN (MAB377, 
Millipore; 1:100), and either PPARδ (PA1-823A, Pierce; 1:200), PPARα (PA1-822A, Pierce; 
1:200), or PPARγ (PA3-821A, Pierce; 1:200), and imaged with a Zeiss LSM 780 inverted 
microscope. Validation of PPARγ immunostaining of brain sections was achieved by 
detection of immunoreactivity in neurons of the hypothalamus, in agreement with previous 
work
41
. For electron microscopy analysis, brains were fixed, embedded, and sectioned, and 
imaged with a Zeiss OM 10 electron microscope. Images were analyzed with the NIH Image 
J program. In all cases, the scorer was blinded to the genotype status of the mice.
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KD3010 was injected intraperitoneally (15 mg/kg) as a suspension in corn oil (3 mg/ml) to 
fasted male C57BL/6J mice. Three cohorts of 3 mice were dosed, and plasma and brains 
were taken at 2, 8, and 24 h, and analyzed by LC-MS/MS (AB Sciex API4000). For plasma 
samples, an aliquot of 10 μl sample was protein precipitated with 100 μl IS, the mixture was 
vortex-mixed for 1 min, and centrifuged at 13000 rpm for 15 min, 20–25 °C. 80 μl 
supernatant was then mixed with 160 μl water/ACN (v:v, 95:5) with 0.1% FA, vortex-mixed 
10 min and centrifuged for 10 min at 4000 rpm, 4 °C. 10 μl sample was injected for LC-
MS/MS analysis. Brain homogenates were prepared by homogenizing brain tissue for 2 min 
with 4 volumes (w:v) of homogenizing solution (deionized water). An aliquot of 60 μl 
sample was protein precipitated with 600 μl IS, the mixture was vortex-mixed for 1 min and 
centrifuged at 13000 rpm for 15 min, 20–25 °C. 80 μl supernatant was then mixed with 160 
μl water/ACN (v:v, 95:5) with 0.1% FA, vortex-mixed 10 min and centrifuged for 15 min at 
4000 rpm, 4 °C. 10 μl sample was injected for LC-MS/MS analysis. A standard curve of 
KD3010 was determined with a LLOQ of 1 ng/ml for plasma and 5 ng/g in brain 
homogenate.
Treatment of mice with KD3010
After genotyping mice, we performed motor baseline assessment prior to group assignments, 
and littermates were randomly assigned to experimental groups while balancing genders, in 
accordance with guidelines intended to avoid spurious results
39,40. Exclusion criteria 
determined prior to the start of the trial were an adverse response to the injections, or death 
prior to start of treatment. These conditions did not occur. After group assignment, 6 week-
old mice were injected initiated daily, five times a week (from Monday to Friday) 
intraperitoneally with 50mg/kg/ day of KD3010 suspended in corn oil (3 mg/ml). Blinded 
observers visually inspected mice for obvious neurological signs and examined mice with a 
composite neurological evaluation tool, as described previously
29
. Blinded investigators 
examined motor phenotypes, by performing rotarod testing, as previously described
20
, as 
well as grip strength and stride length analysis
55
. Cohort sizes were designated based upon 
power analysis for threshold effects of at least 25% difference. For neuropathology 
experiments, brains were harvested as previously described
56,57. Histopathology, volume 
measurements, and stereology analysis were performed, as previously
20
. In all cases, the 
scorer was blinded to the genotype status of the mice.
Bioenergetics assays
Mitochondrial complex activity assays were performed as described previously and adapted 
to a 96-well format
58
. For quantification of ATP, HPLC of adenine nucleotides isolated from 
regions of the brain was performed, as done previously
20
. In all cases, the investigator was 
blinded to the genotype status of the mice.
Transcriptome analysis
RNA-Sequencing (RNA-Seq) was performed by isolating RNA from the striatum of 
individual mice. The Illumina TruSeq™ RNA Sample Preparation Kit was used to prepare 
libraries for sequencing on the Illumina HiSeq 2000 system. RNA-Seq data was mapped 
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with the alignment software GSNAP to the mouse reference genome, obtained from NCBI 
(mm9, Build 37 assembly). The expression of genes was quantified by assigning reads to 
gene locations, determined by the Ensembl gene annotations for mouse, and subsequently 
normalizing to annotated gene length (exons only) and depth of sequencing. Differentially 
expressed genes were called using the local z-score method on pair-wise sample 
comparisons, and were ranked by consistency of differential expression between similar 
comparisons of conditions. Order of magnitude threshold of 20%, a P value cut-off of 0.01, 
and False Discovery Rate of 0.005 were used to identify significantly altered genes upon 
comparison of transgenic samples to non-transgenic controls. A representative subset of 
identified gene expression alterations was validated by qRT-PCR, as above. For gene 
ontology (GO) classification, differentially expressed genes in E411P mice and human HD
35 
were associated with the GO categories of cellular component and biological process. The 
GO enriched biofunctional categories were compared using Ingenuity Pathway Analysis, 
and only GO categories with at least 10 altered genes were reported, and then ranked based 
upon the percentage of altered genes in a particular GO category.
Protein biochemistry analysis
The unbiased screen for htt protein interactors was performed using a Panomics transcription 
factor (TF) immunoprecipitation array, according to the manufacturer’s instructions: http://
www.veritastk.co.jp/attached/2209/TFInteractionArrayKitcombined.pdf. Htt IP for the 
Panomics TF IP array utilized anti-htt antibody EM48. Protein lysates were prepared as 
previously described
55
. For co-immunoprecipitations, homogenized protein was incubated 
with indicated co-immunoprecipitation antibody (GFP: 3E6 A11120, Life Technologies 
(1:100); Htt: MCA2050, Abcam (1:100); PPARδ: SC-7197, Santa Cruz; (1:100)). Proteins 
were run on 10% Bis-Tris gels (Invitrogen) and transferred to PVDF membranes (Millipore) 
prior to blocking in Odyssey Blocking Buffer (LI-COR biosciences). Membranes were 
incubated with antibodies as indicated: Flag (F7425, Sigma; 1:1000), Htt (MAB2166, 
Millipore; 1:1000), GFP (A11121, Life Technologies, 1:1000), PPARδ (PA1-823A, Pierce; 
1:1000), PPARα (PA1-822A, Pierce; 1:1000), or PPARγ (PA3-821A, Pierce; 1:1000), or β-
actin (ab8226, Abcam; 1:10,000), and imaged on the Odyssey instrument (Licor). To obtain 
proteins in vitro for the direct interaction co-immunoprecipitation, the Promega TnT T7 
Quick Coupled Transcription/ Translation System (Promega, #L1170) was used prior to co-
immunoprecipitation.
Stem cell modeling
60i4 HD induced pluripotent stem cells (iPSCs) were differentiated into medium spiny 
neurons for 56 days using a modified protocol
59
, as described previously
60
. On day 42 of 
differentiation, cell aggregates were plated into 24-well plates coated with Matrigel (BD). 
Two weeks later, the cells were transferred to Neural Induction Medium (NIM). KD3010 or 
its enantiomer was added at the time of the medium change to NIM. After 48 h, cells were 
fixed with 4% paraformaldehyde in PBS for 30 min. After 3 washes with PBS, cells were 
stained with 0.8 μg/ml of Hoechst 33342 (Sigma) to visualize cell nuclei. A nuclear 
condensation assay to measure the extent of cell death was performed on 3 different clonal 
lines, as previously described
60
.
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Statistical analysis was done using Microsoft Excel, Prism 4.0 (Graph Pad), or the 
VassarStats website <http://faculty.vassar.edu/lowry/VassarStats.html>. For ANOVA (one-
way), if statistical significance (P < 0.05) was achieved, we performed post-hoc analysis 
corresponding to the experiment, as specified in the figure legend, to account for multiple 
comparisons. Hypergeometric distribution analysis was performed using the Stat Trek 
calculator <http://stattrek.com/online-calculator/hypergeometric.aspx>. All t-tests were two-
tailed unless otherwise indicated, and the level of significance (alpha) was always set at 
0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Huntingtin and PPARδ physically interact
(a) Immunoprecipitation with GFP antibody and immunoblot analysis of GFP-htt-25Q or 
GFP-htt-104Q and Flag-tagged PPARα, -δ, or -γ. GFP-empty-transfected HEK293 cells 
served as a negative control.
(b) Immunoprecipitation of ST-Hdh striatal-like neurons of the indicated genotypes was 
performed with Htt antibody, followed by immunoblot analysis of PPARδ.
(c) Immunoprecipitation of protein lysates from the cortex of 8 month-old BAC-HD mice 
and non-transgenic (Non-Tg) controls with Htt antibody, and immunoblot analysis of 
PPARδ.
(d) Immunoprecipitation of protein lysates from the cortex of 8 month-old BAC-HD mice 
and non-transgenic (Non-Tg) controls with PPARδ antibody, and immunoblot analysis of 
Htt. Note detection of both transgenic polyQ-Htt protein and endogenous mouse Htt protein 
in BAC-HD samples, and detection of endogenous mouse Htt protein in Non-Tg control.
(e) Immunoprecipitation of in vitro transcription-coupled translation of GFP-tagged htt-Q25 
and PPARδ with GFP antibody, followed by immunoblot analysis of PPARδ. For (b) – (e), 
immunoprecipitation with IgG only served as a negative control.
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Figure 2. PPARδ activation rescues transcriptional repression, mitochondrial membrane 
depolarization, and neurotoxicity in HD neurons
(a) 3X-PPRE luciferase reporter activity in primary cortical neurons from BAC-HD or non-
transgenic (Non-Tg) control mice, co-transfected with Renilla luciferase vector, and PPARδ 
and/or PGC-1α expression constructs, as indicated, and treated with GW501516 (100 nM) 
or vehicle. Results were normalized to Non-Tg neurons at baseline. *P < .05; t-test.
(b) Mitochondrial membrane potential of primary cortical neurons from BAC-HD and Non-
Tg mice, treated as indicated, was determined from the ratio of mitochondrial to cytosolic 
JC-1 fluorescence. Results were normalized to Non-Tg neurons at baseline, and CCCP 
treatment served as a positive control for depolarization. *P < .05, **P < .01; t-test.
(c) Immunofluorescence of active caspase-3 (red) and microtubule-associated protein 2 
(green) in primary cortical neurons from BAC-HD and Non-Tg mice, treated as indicated. 
Scale bar = 20 μm.
(d) Quantification of active caspase-3 staining shown in (e). Results were normalized to 
Non-Tg neurons at baseline. *P < .05, **P < .01; t-test.
(e) Cortex from Non-Tg mice immunostained with the indicated PPAR antibody (green) and 
NeuN antibody (red). Merged images reveal expression of indicated PPAR. Scale bar = 50 
μm.
(f) Immunofluorescence of active caspase-3 in primary cortical neurons from BAC-HD 
mice, transfected with the indicated shRNA construct for 3 days, or treated with fenofibrate 
100 nM (PPARα agonist), GW501516 100 nM (PPARδ agonist), or pioglitazone 20 nM 
(PPARγ agonist) for 24 h, prior to exposure to 25 μM H2O2. *P < .05, **P < .01; ANOVA 
with post-hoc Tukey. Error bars = s.e.m. All experiments were performed with 3 biological 
replicates and 9 technical replicates per condition.
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Figure 3. PPARδ transcriptional interference yields neuron dysfunction, and induces 
neurological phenotypes and mitochondrial abnormalities in transgenic mice
(a) RT-PCR analysis of PPARδ target gene expression (left) and ChIP analysis of PPARδ 
occupancy at the promoters of PPARδ target genes (right) in ST-Hdh wild-type (Q7/Q7) and 
homozygous HD mutant (Q111/Q111) striatal-like cells (n = 3 / genotype; 6 – 9 technical 
replicates). **P < .01, *P < .05; t-test.
(b) Nestin-Cre;PPARδ-E411P mice weigh less than littermate control mice. **P < .01; t-test.
(c) Nestin-Cre;PPARδ-E411P mice cannot easily dismount from the cage ledge . **P < .01; 
t-test.
(d) Nestin-Cre;PPARδ-E411P mice exhibit a prominent clasping phenotype. ***P < .001; t-
test.
(e) Nestin-Cre;PPARδ-E411P mice display kyphosis. **P < .01; t-test.
(f) Nestin-Cre;PPARδ-E411P mice attained significantly worse ‘latency to fall’ times on the 
accelerating rotarod . **P < .01, *P < .05; ANOVA with post-hoc Tukey test.
(g) Decreases in mean stride length and reduced combined mesh and triangle grip strength 
were observed for Nestin-Cre;PPARδ-E411P mice. Grip strength is given in arbitrary units 
with littermate control performance set to 1. *P < .05; t-test. For (b) – (g), cohort age was 8 
months, and group sizes were 8 – 9.
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(h) Electron micrographs of mitochondria in striatum neurons of 8 month-old mice of 
indicated genotypes. Scale bar = 1 μm.
(i) Quantification of neuron mitochondrial size in the striatum and cortex, as assessed by 
mitochondrial area and perimeter (n = 4 mice / group). *P < .05; t-test.
(j) HPLC measurement of ATP concentrations in the striatum and cortex of 8 month-old 
mice of indicated genotypes (n = 3 mice / group). *P < .05; t-test. For all experiments, error 
bars = s.e.m.
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Figure 4. Expression of dominant-negative PPARδ in neurons results in widespread 
neurodegeneration
(a) Dissection of whole brain reveals dramatic global atrophy in Nestin-Cre;PPARδ-E411P 
mice. Cortex volume (b) and basal ganglia volume (c) are markedly reduced in Nestin-
Cre;PPARδ-E411P mice. (d) Sections of whole brain stained for NeuN (left), and 
quantification of neuron number (right). Scale bar = 250 μm. (e) Substantia nigra stained for 
tyrosine hydroxylase (TH) (left), and quantification of TH+ neurons (right). Scale bar = 10 
μm. (f) Frontal cortex and hippocampus stained for microtubule-associated protein 2 
(MAP2) (left), and quantification of MAP2 immunoreactivity as a percentage of overall 
neuropil (right). Scale bar (low power) = 100 μm. Scale bar (high power) = 10 μm. (g) 
Cortex and basal ganglia stained for GFAP (left), and quantification of overall GFAP 
immunoreactivity (right). Scale bar = 100 μm.
For all experiments, *P < .05; t-test, cohort age was 10 months, group sizes were 4 – 6, and 
error bars = s.e.m.
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Figure 5. Dominant-negative PPARδ expression in the striatum recapitulates HD-like motor 
dysfunction and transcriptional pathology
(a) Rgs9-Cre;PPARδ-E411P mice cannot easily dismount from the cage ledge. *P < .05; t-
test.
(b) Rgs9-Cre;PPARδ-E411P mice exhibit a prominent clasping phenotype. *P < .05; t-test.
(c) Rgs9-Cre;PPARδ-E411P mice display kyphosis. *P < .05; t-test.
(d) Rgs9-Cre;PPARδ-E411P mice exhibit impaired motor coordination on the accelerating 
rotarod. *P < .05; ANOVA with post-hoc Tukey test.
(e) Mesh grip strength analysis. Grip strength is given in arbitrary units with littermate 
control performance set to 1. *P < .05; t-test.
For (a) – (e), cohort age was 9 months, and group sizes were 7.
(f) Sections of striatum from 10 month-old Rgs9-Cre;PPARδ-E411P mice and littermate 
controls were immunostained for NeuN. Representative insets indicate reduced striatal 
neuron number in Rgs9-Cre;PPARδ-E411P mice. Scale bar (low power) = 200 μm; Scale bar 
(inset) = 20 μm.
(g) Quantification of neuron number from (f). *P < .05; t-test. n = 4 mice / group.
(h) RNA-Seq analysis on striatum from 10 month-old Nestin-Cre;PPARδ-E411P mice and 
littermate control mice (n = 3 / group). Pie charts indicate the percentage of genes for the 
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highest ranked altered ‘Biofunctions’ pathways in microarray expression data from human 
HD caudate
35
 (left) and RNA-Seq analysis of PPARδ-E411P mouse striatum (right). Error 
bars = s.e.m.
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Figure 6. Treatment with the PPARδ agonist KD3010 improves motor function, 
neurodegeneration, and survival in HD mice, and rescues neurotoxicity in human HD neurons
Composite neurological examination (a) and accelerating rotarod analysis (b) of HD mice, 
receiving vehicle or KD3010, and non-transgenic (Non-Tg) littermate controls, at indicated 
ages. ***P < .001, **P < .01, *P < .05; ANOVA with post-hoc Tukey test. Cohort sizes were 
as follows: 9 Non-Tg controls, 13 HD mice on vehicle, and 12 HD mice on KD3010.
(c) Evaluation of neuropathology in striatum. Quantification of striatal choline 
acetyltransferase (ChAT) immunoreactivity (left), striatal htt aggregation (EM48) (center), 
and striatal volume by stereology (right) for 18 week-old HD mice receiving vehicle or 
KD3010 (n = 4 – 5 mice/group). **P < .01, *P < .05; t-test.
(d) Kaplan-Meier plot reveals extended lifespan in HD mice receiving KD3010. *P < .05, 
Log-rank test.
(e) Quantification of neuron cell death for medium spiny-like neurons differentiated from 
iPSC lines derived from a HD individual with a 60Q allele, and treated with KD3010 at the 
indicated concentrations, BDNF at 20 ng/ml (positive control), or the inactive enantiomer of 
KD3010 at 1 μM (negative control). Untreated neurons served as another negative control 
(Ctrl). **P < .01, *P < .05; ANOVA with post-hoc Bonferroni test. Error bars = s.e.m.
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